Genovis Launches A Follow-Up To FabRICATOR

Genovis is launching a follow-up to FabRICATOR®, marketed under the name FabRICATOR®Z, for customers primarily in the pharmaceutical industry for preclinical research.

Genovis’ products are marketed under the name SmartEnzymes and are largely used in preclinical research and pharmaceutical production. FabRICATOR®Z is a recombinant protein that cleaves an antibody into two parts: a Fab fragment and an Fc fragment. In contrast to Genovis’ best-seller FabRICATOR, FabRICATOR®Z also cleaves a specific type of mouse IgG quickly and more effectively than FabRICATOR and the other enzymes on the market. The product complements FabRICATOR® and FabULOUS® and will be introduced this week at the PEGS conference in Boston.

“FabRICATOR®Z is a product that offers better performance for certain types of antibodies that our customers work with. The improved performance, especially for mouse IgG2a compared with FabRICATOR, also paves the way for new applications, including in diagnostics, where this type of antibody is commonly found. It is gratifying to be able to launch another product that we have developed by working closely with our customers,” says Fredrik Olsson, CEO at Genovis.

For more information about FabRICATOR®Z: www.genovis.com/FabRICATOR_Z

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233

fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Help employers find you! Check out all the jobs and post your resume.

Back to news